05.08Page 9Clinical Trials: Case StudiesCase 1: Dexamethasone & PharyngitisPrimary & Secondary Results
05.08Page 11Clinical Trials: Case StudiesCase 1: Dexamethasone & PharyngitisWhy No Baseline Statistical Test
05.08Page 13Clinical Trials: Case StudiesCase 1: Dexamethasone & PharyngitisRisk Difference & Relative Risk
05.08Page 14Clinical Trials: Case StudiesCase 1: Dexamethasone & Pharyngitis24h Result Interpretation
05.08Page 15Clinical Trials: Case StudiesCase 1: Dexamethasone & PharyngitisConfidence Interval Interpretation
05.08Page 22Clinical Trials: Case StudiesCase 3: Streptomycin & TuberculosisResults & P-value Misinterpretation
05.08Page 23Clinical Trials: Case StudiesCase 3: Streptomycin & TuberculosisContributions & Remaining Gaps
05.08Page 24Clinical Trials: Case StudiesCase 4: Myocardial Infarction (ISIS-2)Mechanism & Treatments
05.08Page 25Clinical Trials: Case StudiesCase 4: Myocardial Infarction (ISIS-2)Factorial Trial Design
05.08Page 26Clinical Trials: Case StudiesCase 4: Myocardial Infarction (ISIS-2)Main Result: 35-Day Mortality
05.08Page 27Clinical Trials: Case StudiesCase 4: Myocardial Infarction (ISIS-2)Lancet Subgroup Pressure
05.08Page 28Clinical Trials: Case StudiesCase 4: Myocardial Infarction (ISIS-2)Zodiac Subgroup & Type 1 Error
05.08Page 33Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19In Vitro Evidence (2005)
05.08Page 34Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19Marseille Non-Randomized Study
05.08Page 35Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19Media & Policy Before Evidence
05.08Page 38Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19RECOVERY Randomization Schema
05.08Page 39Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19HCQ Ineffective (RECOVERY)
05.08Page 40Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19Dexamethasone Effective (RECOVERY)
05.08Page 41Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19Dexamethasone Stratified by Severity
05.08Page 42Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19Average Effect & Subgroup Heterogeneity
05.08Page 43Clinical Trials: Case StudiesCase 6: Hydroxychloroquine & COVID-19RECOVERY Results Summary